105
Participants
Start Date
December 8, 2020
Primary Completion Date
December 5, 2024
Study Completion Date
December 5, 2024
CVL-865
Participants will receive 25 mg CVL-865 tablets orally BID during the treatment period. The dose may be decreased to 17.5 mg BID for tolerability.
Randwick, New South Wales, Randwick
Camperdown, New South Wales, Camperdown
Westmead, New South Wales, Westmead
Melbourne, Victoria, Melbourne
Parkville, Victoria, Parkville
Fitzroy, Victoria, Fitzroy
Heidelberg, Victoria, Heidelberg
Herston, Queensland, Herston
New York, New York
Rochester, New York, Rochester
Philadelphia, Pennsylvania, Philadelphia
Philadelphia, Pennsylvania, Philadelphia
Bethesda, Maryland, Bethesda
Baltimore, Maryland, Baltimore
Madrid, Madrid
Madrid, Madrid
Malaga,, Málaga
Charleston, South Carolina, Charleston
Jacksonville, Florida, Jacksonville
Orlando, Florida, Orlando
Miami Lakes, Florida, Miami Lakes
Tampa, Florida, Tampa
Port Charlotte, Florida, Port Charlotte
Kragujevac, Sumadija, Kragujevac
Neurology Department, Kragujevac, Kragujevac
Nashville, Tennessee, Nashville
Lexington, Kentucky, Lexington
Sevilla, Seville
Toledo, Ohio, Toledo
Valencia, Valencia
Chesterfield, Missouri, Chesterfield
Saint Louis, Missouri, St Louis
Little Rock, Arkansas, Little Rock
Oklahoma City, Oklahoma, Oklahoma City
Lviv, Lviv
Salt Lake City, Utah, Salt Lake City
Uzhgorod, Uzhhorod
Honolulu, Hawaii, Honolulu
New Haven, Connecticut, New Haven
Gulf Breeze, Florida, Gulf Breeze
Scarborough, Maine, Scarborough
Boston, Massachusetts, Boston
Hackensack, New Jersey, Hackensack
Bydgoszcz, Kujawsko-Pomorskie, Bydgoszcz
Kraków, Malopolskie, Krakow
Gdańsk, Pomorskie, Gdansk
Wojnicz, Lskie, Wojnicz
Białystok, Bialystok
Warszawa, Warsaw
Lodz, Lodz
Gwangjin-gu, Seoul, Gwangju
Irwon-Ro Gangnam-gu., Seoul, Irwon-dong
Barcelona, Catalunya, Barcelona
Barcelona, Catalonia, Barcelona
Terrassa, Catalonia, Terrassa
Kyiv, Kyiv
Lead Sponsor
AbbVie
INDUSTRY